Inês Borges

Dr. Inês Borges

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Tiago Bordeira GasparTiago Bordeira Gaspar
Tiago Bordeira Gaspar
TJTito Teles Teles Jesus
Tito Teles Teles Jesus
MAMaria Teresa Azevedo
Maria Teresa Azevedo
Sofia MacedoSofia Macedo
Sofia Macedo
MSMariana Alves Soares
Mariana Alves Soares
JVJoão Vinagre
João Vinagre
Atrx loss was recently ascertained as insufficient to drive pancreatic neuroendocrine tumour (PanNET) formation in mice islets. We have identified a preponderant role of Atrx in the endocrine dysfunction in a Rip-Cre;AtrxKO genetically engineered mouse model (GEMM). To validate the impact of a different Cre-driver line, we used similar methodologies and characterised the Pdx1-Cre;AtrxKO (P.AtrxKO) GEMM to search for PanNET formation and endocrine fitness disruption for a period of up to 24 months. Male and female mice presented different phenotypes. Compared to P.AtrxWT, P.AtrxHOM males were heavier during the entire study period, hyperglycaemic between 3 and 12 mo., and glucose intolerant only from 6 mo.; in contrast, P.AtrxHOM females started exhibiting increased weight gains later (after 6 mo.), but diabetes or glucose intolerance was detected by 3 mo. Overall, all studied mice were overweight or obese from early ages, which challenged the histopathological evaluation of the pancreas and liver, especially after 12 mo. Noteworthily, losing Atrx predisposed mice to an increase in intrapancreatic fatty infiltration (FI), peripancreatic fat deposition, and macrovesicular steatosis. As expected, no animal developed PanNETs. An obese diabetic GEMM of disrupted Atrx is presented as potentially useful for metabolic studies and as a putative candidate for inserting additional tumourigenic genetic events.

24 June 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
AMAlexandra Filipa Rocha Monteiro
Alexandra Filipa Rocha Monteiro
Tiago Bordeira GasparTiago Bordeira Gaspar
Tiago Bordeira Gaspar
IBInês Borges
Inês Borges
Sule CANBERKSule CANBERK
Sule CANBERK
MPMafalda Pinto
Mafalda Pinto
CTCatarina Tavares
Catarina Tavares
Thyroid tumors are common in humans and cats, occurring most commonly as benign lesions, whereas thyroid carcinoma is barely detected in both species. Determining the mutational status of MAPK-related genes (BRAF, NRAS, HRAS, and KRAS) and the activation status of MAPK and mTOR pathways is crucial for establishing the diagnosis, treatment, and prognosis of human patients. So far, the role of such players in feline thyroid tumorigenesis remains underexplored. This study aims to elucidate the presence and implications of potential shared molecular mechanisms between human and feline thyroid tumors. Fifteen formalin-fixed paraffin-embedded feline thyroid epithelial tumors (four tumors with atypia and 11 with no atypia) were collected to perform mutational and immunohistochemical analyses. Sanger sequencing targeting human homologous hotspots revealed no mutations in BRAF (human codon 600) or RAS (human codon 61) regions. A KRAS missense mutation (p.Gln232His) was identified in two tumors with no atypia of follicular pattern (2/15, 13%). Regardless of the mutational status, pERK (Thr202/Ty204) was immuno-expressed in 10/11 (91%), pS6 (Ser235/236) in 100%, and pAKT (Ser473) in 8/11 (73%) of the tumors with no atypia. The expression patterns of pERK, pS6, and pAKT and their associations with clinical-pathological features seem to mirror the progression dynamics observed in human thyroid tumorigenesis. pAKT expression was associated with the presence of multiple tumor foci within the same thyroid lobe, suggesting its potential as a marker of aggressiveness in feline thyroid tumors. This study introduces cats as potential animal models for human thyroid tumorigenesis, with further research required to confirm such potential.

9 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Filipe SampaioFilipe Sampaio
Filipe Sampaio
Hugo Lima de CarvalhoHugo Lima de Carvalho
Hugo Lima de Carvalho
GBGonçalo Barros
Gonçalo Barros
IBInês Borges
Inês Borges
Cátia C. E. FernandesCátia C. E. Fernandes
Cátia C. E. Fernandes
Ricardo Manuel Vinagre LopesRicardo Manuel Vinagre Lopes
Ricardo Manuel Vinagre Lopes
Feline infectious peritonitis (FIP) remains diagnostically challenging, and rapid antemortem confirmation is increasingly important in the era of effective antiviral therapy. This pilot diagnostic accuracy study assessed agreement between effusion RT-qPCR and cell tube block immunohistochemistry (CTB-IHC) in 40 cats with suspected FIP and developed an exploratory effusion-based predictive score using CTB-IHC as the reference standard. RT-qPCR and CTB-IHC showed almost perfect agreement (κ = 0.86): 30 cats were positive by both methods, eight were negative by both, and two were CTB-IHC-positive/RT-qPCR-negative. RT-qPCR showed 93.8% sensitivity (95% CI: 79.2–99.2%), 100% specificity (63.1–100%), and 95.0% accuracy (83.1–99.4%). The three-parameter FIP Predictive Score, combining globulin concentration, FIP Effusion Index, and A:G ratio, achieved an apparent AUC of 0.916 (95% CI: 0.842–0.990), with 78.1% sensitivity (60.0–90.7%) and 100% specificity (63.1–100%) at ≥ 2 points. Given that the score was derived and evaluated within the same small cohort, independent external validation is essential before clinical implementation. Nevertheless, neither a low score nor a negative molecular result should independently close investigation when FIP remains clinically suspected. These findings provide a foundation for a structured, multimodal effusion-based diagnostic approach integrating molecular, antigen, biochemical, and cytometric evidence.